3.66
-0.12(-3.17%)
Currency In USD
| Previous Close | 3.78 |
| Open | 3.79 |
| Day High | 3.85 |
| Day Low | 3.6 |
| 52-Week High | 20.7 |
| 52-Week Low | 2.71 |
| Volume | 49,336 |
| Average Volume | 156,387 |
| Market Cap | 11.68M |
| PE | -0.45 |
| EPS | -8.07 |
| Moving Average 50 Days | 3.87 |
| Moving Average 200 Days | 6.44 |
| Change | -0.12 |
If you invested $1000 in Cellectar Biosciences, Inc. (CLRB) 10 years ago, it would be worth $0.13 as of December 13, 2025 at a share price of $3.66. Whereas If you bought $1000 worth of Cellectar Biosciences, Inc. (CLRB) shares 5 years ago, it would be worth $5.89 as of December 13, 2025 at a share price of $3.66.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Cellectar Biosciences to Report Third Quarter Financial Results and Host a Conference Call on Thursday, November 13, 2025
GlobeNewswire Inc.
Nov 06, 2025 1:05 PM GMT
FLORHAM PARK, N.J., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced that th
Cellectar Biosciences Receives Rare Pediatric Disease Designation from U.S. Food and Drug Administration for Iopofosine I 131 in Relapsed or Refractory Pediatric High-Grade Glioma
GlobeNewswire Inc.
Oct 27, 2025 12:30 PM GMT
CLOVER-2 Phase 1 Clinical Study Evaluating Iopofosine I 131 in Relapsed/Refractory Pediatric High-Grade Glioma Patients Showed Extended Progression Free Survival and Overall SurvivalFLORHAM PARK, N.J., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Cellectar Bi
Cellectar Biosciences Presented Promising Preclinical Data in Poster Presentation at the American Association for Cancer Research (AACR) Special Conference on Pancreatic Cancer Research
GlobeNewswire Inc.
Oct 14, 2025 12:30 PM GMT
CLR 225 (225Ac-phospholipid ether) Demonstrates Meaningful Inhibition of Tumor Growth and Potential Survival Benefit In Three Pancreatic Cancer Xenograft ModelsFLORHAM PARK, N.J., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDA